SPECIALTY TOPICS · GUIDE
Claim Check: "Reducing All Inflammation"
Why "reduces inflammation" is not the same as better health, with trial evidence that lowering inflammation markers helped in one trial, failed in another and raised infection risk.
Content last updated . This page has not been medically reviewed.
Back to Emerging Wellness ScienceThe claim
"Reduces all inflammation" appears on foods, supplements, devices and programs. The claim treats inflammation as one bad thing that should be switched off. This page checks that idea. Labels used: marketing claim, established, mixed, evidence of harm.Inflammation is not one thing
MedlinePlus explains that inflammation is the body's way of protecting tissues and helping them heal from injury, infection or other disease, and that when it is sudden and short it is helpful. [1] Long-lasting inflammation is a different situation; see acute vs chronic inflammation. A product that lowers "all" inflammation would also, in principle, lower the part that fights infection and repairs tissue. The claim does not say which inflammation, where, or measured how.What a marker can and cannot tell you
The common blood marker CRP shows how much inflammation is present, but not what is causing it or where it is. [1] Levels can also rise with insomnia, depression, menopause hormone therapy and obesity. [1] A fall in CRP after a product is a lab change. Whether it means better health must be shown in a trial with real outcomes. Panels are covered in inflammatory panels and their limits.Two trials that targeted inflammation on purpose
Both enrolled people who already had heart disease, so they do not apply to healthy people.| CANTOS (canakinumab) | CIRT (low-dose methotrexate) | |
|---|---|---|
| People | 10,061 people with a previous heart attack and high-sensitivity CRP of 2 mg/L or more [2] | 4,786 people with previous heart attack or multivessel coronary disease plus type 2 diabetes or metabolic syndrome [3] |
| Inflammation markers | CRP fell more than with placebo [2] | No lower interleukin-1β, interleukin-6 or CRP than placebo [3] |
| Heart outcome | The 150 mg dose, but not the other doses, met the prespecified threshold (hazard ratio 0.85, 95% CI 0.74 to 0.98) [2] | No fewer cardiovascular events (hazard ratio 0.96, 95% CI 0.79 to 1.16) [3] |
| Harms | More fatal infection than placebo; no significant difference in all-cause death [2] | Higher liver enzymes, lower white blood cell counts, more non-basal-cell skin cancers [3] |
CANTOS was funded by the drug maker. [2] Canakinumab is a prescription drug given under medical care, not a food or supplement, and neither result supports a general claim. Lowering one specific inflammatory pathway helped one heart outcome in a selected group at the price of more serious infection. Lowering inflammation another way did nothing.
Where the evidence stops
- Food, supplement and device claims need their own trials with health outcomes. Nutrition research is in nutrition and inflammation research.
- A drug result in heart patients cannot be moved to people without that condition, or to products.
- A related check: "reduces inflammation" means improves health.
Frequently asked questions
Is inflammation always bad?
No. Short-term inflammation helps protect and heal tissues. [1]
If a product lowers CRP, is it healthier?
Not shown by that alone. In CIRT the drug did not lower CRP and did not reduce heart events; in CANTOS CRP fell, but benefit was limited to one dose and fatal infections rose. [3][2]
Does lowering inflammation prevent infections?
No. In CANTOS the inflammation-lowering drug was linked to more fatal infection than placebo. [2]
Can a CRP test tell me what is wrong?
No. It shows how much inflammation is present, not the cause or place. [1]
More details: evidence, limits and cautions
The details behind this page: cautions, limits of the evidence and where sources disagree. Open any note to read it.
Safety and when to get help
References
- MedlinePlus (US National Library of Medicine), C-Reactive Protein (CRP) Test. Read 2026-10-22.
- Ridker PM et al. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease (CANTOS). N Engl J Med 2017. PubMed 28845751. Read 2026-10-22.
- Ridker PM et al. Low-Dose Methotrexate for the Prevention of Atherosclerotic Events (CIRT). N Engl J Med 2019. PubMed 30415610. Read 2026-10-22.